Ser385
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser385  -  GIRK1 (human)

Site Information
NSKERHNsVECLDGL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4706226

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 4 ) , mutation of modification site ( 2 , 3 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 4 ) , non-small cell lung cancer ( 4 ) , non-small cell lung adenocarcinoma ( 4 ) , non-small cell squamous cell lung carcinoma ( 4 )
Relevant cell line - cell type - tissue:
breast ( 1 ) , NCI-H1703 (squamous) ( 4 ) , oocyte ( 2 , 3 )

Upstream Regulation
Putative in vivo kinases:
PKACA (human) ( 3 )
Kinases, in vitro:
PKACA (human) ( 3 )
Treatments:
colforsin ( 3 ) , H-89 ( 3 )

Downstream Regulation
Effects of modification on GIRK1:
activity, induced ( 3 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Treiber F, et al. (2013) Molecular basis of the facilitation of the heterooligomeric GIRK1/GIRK4 complex by cAMP dependent protein kinase. Biochim Biophys Acta 1828, 1214-21
23305758   Curated Info

3

Rusinova R, et al. (2009) Mass spectrometric analysis reveals a functionally important PKA phosphorylation site in a Kir3 channel subunit. Pflugers Arch 458, 303-14
19151997   Curated Info

4

Moritz A (2007) CST Curation Set: 2762; Year: 2007; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621
Curated Info